Zejula-Keytruda Trial Results Warrant Further Investigation for Recurrent OC

Zejula-Keytruda Trial Results Warrant Further Investigation for Recurrent OC
A combination of Zejula (niraparib) and Keytruda (pembrolizumab) is well-tolerated and has promising anti-tumor activity in women with ovarian carcinoma who have failed prior platinum-based chemotherapy, results from a Phase 1/2 trial show. Overall, 18% of the patients responded to the combo regimen, regardless of platinum resistance, BRCA mutations, or prior treatment with bevacizumab (brand names Avastin, Mvasi, and Zirabev), warranting further investigation in a larger trial, the researchers said. Response rates seemed particularly significant for patients without BRCA or other DNA repair mutations. The data were described in the report, "Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma," published in the journal JAMA Oncology. Zejula is approved as a maintenance therapy for recurrent epithelial ovarian,
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *